Table of Contents
When did Lonza go public?
21 October 2011
Lonza Group Lp (SIX stock code: LONN VX; SGX-ST stock code: O6Z) makes its trading debut on the Main Board of the Singapore Exchange Securities Trading Limited (“SGX-ST”) on 21 October 2011 and consequently is the first SIX Swiss-listed company to dual list in Singapore.
Who owns Lonza Pharmaceuticals?
Lonza Group
| The Lonza Tower in Basel, Switzerland. | |
|---|---|
| Founded | 1897 |
| Headquarters | Basel, Switzerland |
| Key people | Pierre-Alain Ruffieux (CEO) |
| Products | Biopharmaceuticals, organic and fine chemicals, chemical synthesis equipment, custom manufacturing of chemicals and related products |
Who are Lonza competitors?
Lonza’s top competitors include Tokuyama, Nissan Chemical, Novozymes, WuXi Biologics, DuPont, Bristol-Myers Squibb, Catalent, Royal DSM and Divis Laboratories.
Is Lonza a Cdmo?
Even as COVID-19 manufacturing dominates headlines, Swiss CDMO juggernaut Lonza is taking steps to keep the rest of its production arsenal competitive. At the company’s site in Visp, Switzerland, Lonza plans to spend 650 million Swiss francs (about $715 million) on a large-scale mammalian drug substance factory.
Is Lonza a good buy?
Lonza Group Ag (LZAGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
How many employees does Lonza have?
15,000 employees
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 15,000 employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate.
Where is Lonza in Switzerland?
Basel, Switzerland
The Drug Product Services group is located in Basel, Switzerland with state-of-the-art analytical, formulation and drug product processing equipment, and unparalleled expertise in parenteral drug product development, manufacturing and testing.
What is Lonza revenue?
4.508 billion CHF (2020)
Lonza Group AG/Revenue
How many people work at Lonza?
What is Lonza famous for?
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We focus on enabling treatments that prevent illness and support healthier lifestyles. We optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers.
How is it to work at Lonza?
Very intense but rewarding work environment Lonza overall is a solid career move if you have experience in Therapeutic Protein Manufacturing or education in environmental science or bioscience. Working in the Suites is very fast paced but people are often very helpful in making sure new team members aren’t left behind.
Is Lzagy a buy?
Where is the Lonza Group of companies located?
Lonza Group. Lonza Group is a Swiss multinational, chemicals and biotechnology company, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical…
When did Lonza merge with Alusuisse-Lonza Group?
Lonza de-merged from the Alusuisse-Lonza Group in 1999 and listed on the SWX Swiss Exchange . The company expanded in the United States in 1969 and acquired smaller biopharmaceutical units in recent years. In 1996, Lonza acquired Celltech Biologics and began producing mammalian cell cultures and monoclonal antibodies.
Who was the first president of Lonza AG?
Alphons Mathias Ehinger-Heusler first president of Lonza. Construction work began at the Visp plant in Switzerland, as the site in Gampel was too becoming too small. The site was then opened in 1909. Lonza moved its head office to Basel, Switzerland.
Where can I find the Lonza annual report?
All financially relevant Lonza publications in one place All publications Annual Report 2020 Creating value in 2020 and investing for the future Visit the website Consensus and Analysts Credit Information Frequently Asked Questions News Corporate Governance